Change search
ReferencesLink to record
Permanent link

Direct link
Three-Dimensional Cell Culture-Based Screening Identifies the Anthelmintic Drug Nitazoxanide as a Candidate for Treatment of Colorectal Cancer
Uppsala University, Sweden.
Karolinska Institute, Sweden.
Karolinska Institute, Sweden.
Adlego Biomed AB, Sweden.
Show others and affiliations
2015 (English)In: Molecular Cancer Therapeutics, ISSN 1535-7163, E-ISSN 1538-8514, Vol. 14, no 6, 1504-1516 p.Article in journal (Refereed) Published
Abstract [en]

Because dormant cancer cells in hypoxic and nutrient-deprived regions of solid tumors provide a major obstacle to treatment, compounds targeting those cells might have clinical benefits. Here, we describe a high-throughput drug screening approach, using glucose-deprived multicellular tumor spheroids (MCTS) with inner hypoxia, to identify compounds that specifically target this cell population. We used a concept of drug repositioning-using known molecules for new indications. This is a promising strategy to identify molecules for rapid clinical advancement. By screening 1,600 compounds with documented clinical history, we aimed to identify candidates with unforeseen potential for repositioning as anticancer drugs. Our screen identified five molecules with pronounced MCTS-selective activity: nitazoxanide, niclosamide, closantel, pyrvinium pamoate, and salinomycin. Herein, we show that all five compounds inhibit mitochondrial respiration. This suggests that cancer cells in low glucose concentrations depend on oxidative phosphorylation rather than solely glycolysis. Importantly, continuous exposure to the compounds was required to achieve effective treatment. Nitazoxanide, an FDA-approved antiprotozoal drug with excellent pharmacokinetic and safety profile, is the only molecule among the screening hits that reaches high plasma concentrations persisting for up to a few hours after single oral dose. Nitazoxanide activated the AMPK pathway and downregulated c-Myc, mTOR, and Wnt signaling at clinically achievable concentrations. Nitazoxanide combined with the cytotoxic drug irinotecan showed anticancer activity in vivo. We here report that the FDA-approved anthelmintic drug nitazoxanide could be a potential candidate for advancement into cancer clinical trials. (C) 2015 AACR.

Place, publisher, year, edition, pages
American Association for Cancer Research , 2015. Vol. 14, no 6, 1504-1516 p.
National Category
Clinical Medicine
URN: urn:nbn:se:liu:diva-120662DOI: 10.1158/1535-7163.MCT-14-0792ISI: 000358054300025PubMedID: 25911689OAI: diva2:847544

Funding Agencies|Swedish Cancer Society; Swedish Foundation for Strategic Research; Swedish Research Council; Lions Cancer Research Fund; Strategiska Forskningsstiftelsen (SSF); Lions Cancerforskningsfond; Cancerfonden; Barncancerfonden; Radiumhemmets Forskningsfonder; Vetenskapsradet; SSF

Available from: 2015-08-20 Created: 2015-08-20 Last updated: 2015-08-26

Open Access in DiVA

fulltext(1207 kB)5 downloads
File information
File name FULLTEXT01.pdfFile size 1207 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Linder, Stig
By organisation
Division of Drug ResearchFaculty of Medicine and Health Sciences
In the same journal
Molecular Cancer Therapeutics
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar
Total: 5 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 41 hits
ReferencesLink to record
Permanent link

Direct link